文献速递妇科

宫颈癌患者复发后生存情况研究

Post-recurrence survival in patients with cervical cancer.
PubMed 文献 · Gynecol Oncol · 2021-12-23

基于SCANN研究中528例2007—2016年首次手术后复发的早期宫颈癌患者,分析复发后疾病特异性生存(PR-DSS)及其预后因素。5年PR-DSS为39.1%(95%CI 22.7%-44.5%),多变量模型纳入6个常规记录的预后标志物,交叉验证后C统计量为0.701(95%CI 0.675-0.727),并区分出三个预后显著不同的风险组。

要点

  • 5年PR-DSS为39.1%(95%CI 22.7%-44.5%),复发后中位生存2.5年。
  • 模型纳入6个预后标志物:最大肿瘤大小、淋巴血管间隙浸润、DFI1、复发时年龄、症状、复发类型。
  • 三个风险组5年PR-DSS分别为81.8%、44.6%、12.7%。

核心结论

  • 作者利用6个常规记录的预后标志物构建了复发后疾病特异性生存的预后模型,可将复发宫颈癌患者按风险分层,作者认为该模型可用于临床实践以辅助复发管理决策并更好地告知患者。

研究设计与样本

  • 数据来自SCANN研究(Surveillance in Cervical CANcer),纳入528例2007—2016年首次手术后复发的早期宫颈癌患者。
  • 将原发疾病和复发相关因素纳入多变量Cox比例风险模型预测PR-DSS。

主要发现

  • 5年PR-DSS为39.1%(95%CI 22.7%-44.5%),原发手术至复发的中位无病间期(DFI1)为1.5年,复发后中位生存为2.5年。
  • 多变量分析识别出6个显著变量并用于构建预后模型:2个与原发治疗相关(最大肿瘤大小和淋巴血管间隙浸润),4个与复发相关(DFI1、复发时年龄、是否存在症状、复发类型)。
  • 预后模型10折交叉验证后的C统计量为0.701(95%CI 0.675-0.727)。
  • 识别出三个预后显著不同的风险组,5年PR-DSS分别为81.8%、44.6%和12.7%。

关键数值与推荐

  • 模型纳入的6个预后标志物:最大肿瘤大小、淋巴血管间隙浸润、DFI1、复发时年龄、症状、复发类型。
  • 预后模型10折交叉验证后C统计量为0.701(95%CI 0.675-0.727)。
  • 三个风险组5年PR-DSS分别为81.8%、44.6%、12.7%。

临床怎么用

  • 作者认为该模型可用于临床实践,辅助复发管理策略的决策并更好地告知患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Up to 26% of patients with early-stage cervical cancer experience relapse after primary surgery. However, little is known about which factors influence prognosis following disease recurrence. Therefore, our aims were to determine post-recurrence disease-specific survival (PR-DSS) and to identify respective prognostic factors for PR-DSS. METHODS: Data from 528 patients with early-stage cervical cancer who relapsed after primary surgery performed between 2007 and 2016 were obtained from the SCANN study (Surveillance in Cervical CANcer). Factors related to the primary disease and recurrence were combined in a multivariable Cox proportional hazards model to predict PR-DSS. RESULTS: The 5-year PR-DSS was 39.1% (95% confidence interval [CI] 22.7%-44.5%), median disease-free interval between primary surgery and recurrence (DFI1) was 1.5 years, and median survival after recurrence was 2.5 years. Six significant variables were identified in the multivariable analysis and were used to construct the prognostic model. Two were related to primary treatment (largest tumour size and lymphovascular space invasion) and four to recurrence (DFI1, age at recurrence, presence of symptoms, and recurrence type). The C-statistic after 10-fold cross-validation of prognostic model reached 0.701 (95% CI 0.675-0.727). Three risk-groups with significantly differing prognoses were identified, with 5-year PR-DSS rates of 81.8%, 44.6%, and 12.7%. CONCLUSIONS: We developed the robust model of PR-DSS to stratify patients with relapsed cervical cancer according to risk profiles using six routinely recorded prognostic markers. The model can be utilised in clinical practice to aid decision-making on the strategy of recurrence management, and to better inform the patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cibula D, Dostálek L, Jarkovsky J, et al. Post-recurrence survival in patients with cervical cancer. Gynecol Oncol. 2021. PMID: 34955236. doi:10.1016/j.ygyno.2021.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。